Oxbryta (Voxelotor) Patent Expiration, LOE Window & CMS Spending
Oxbryta (Voxelotor) by Pfizer: FDA Orange Book core substance LOE 2035-02-06 (last listed 2037-10-12), 0 AB generics, $195.8M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pfizer |
| FDA Application & Pathway | N213137 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2035-02-06 |
| Last Listed Patent or Exclusivity Date | 2037-10-12 |
| Orange Book Patents (*PED Extensions) | 11 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $195.8M |
| 2024 Medicare Part D Spend | $77.2M |
| 2024 Medicaid Spend | $118.6M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 20.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.